Literature DB >> 24328873

Long-term monitoring of brain tumors: when is it necessary?

Jeffrey Kennedy1, Stephan U Schuele.   

Abstract

Tumors, particularly low grade glioma and glioneuronal tumors, account for 25-35% of patients who are undergoing epilepsy surgery for intractable seizures. A comprehensive epilepsy evaluation including video-electroencephalography (EEG) monitoring is useful for most of these patients, to determine the optimal extent of resection for the achievement of seizure-free outcome without causing postoperative deficits. Video-EEG monitoring for patients with brain tumor should also be considered in specific situations, such as patients with new postoperative seizures or advanced tumors with unexplained mental status change. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Continuous EEG monitoring; Glioneuronal tumors; Nonconvulsive status epilepticus; Presurgical evaluation; Psychogenic seizures; Tumor-related epilepsy

Mesh:

Year:  2013        PMID: 24328873     DOI: 10.1111/epi.12444

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

1.  Early glioma is associated with abnormal electrical events in cortical cultures.

Authors:  Jude Pj Savarraj; Kinsey Cotton Kelly; Mark A DeCoster
Journal:  Med Biol Eng Comput       Date:  2019-05-11       Impact factor: 2.602

2.  Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials-impact of psychogenic non-epileptic seizures.

Authors:  Amy M Morrow; Rachael M Morgan; John L Villano
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

Review 3.  A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.

Authors:  Ingmar Blumcke; Eleonora Aronica; Horst Urbach; Andreas Alexopoulos; Jorge A Gonzalez-Martinez
Journal:  Acta Neuropathol       Date:  2014-05-25       Impact factor: 17.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.